Floatz logo

124 assets in Leukemia

Therapeutic assets addressing Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ponatinib
Leukemia
M.D. Anderson Cancer CenterP2CCC (52)
Therapeutic Autologous Lymphocytes
Leukemia
Memorial Sloan Kettering Cancer CenterP1/2CCC (52)
Lactobacillus Plantarum Strain 299V
Leukemia
Children's Oncology GroupP3CCC (51)
Tocilizumab
Leukemia
Insel Gruppe AG, University Hospital BernP2CCC (51)
Valaciclovir
Leukemia
M.D. Anderson Cancer CenterP2CCC (51)
Amoxicillin
Leukemia
Monash UniversityP2/3CCC (50)
Clavulanic Acid
Leukemia
Monash UniversityP2/3CCC (50)
Sulfamethoxazole
Leukemia
Monash UniversityP2/3CCC (50)
Trimethoprim
Leukemia
Monash UniversityP2/3CCC (50)
Revumenib
Leukemia
Memorial Sloan Kettering Cancer CenterP1/2CCC (49)
Zanubrutinib
Leukemia
Inhye AhnP1/2CCC (49)
Allo-Quadcar01-T
Leukemia
AvenCell Therapeutics, Inc.P1/2CCC (48)
cd123-car-nk cells
Leukemia
Chongqing Precision Biotech Co., LtdP1/2CCC (48)
Degarelix
Leukemia
Memorial Sloan Kettering Cancer CenterP2CCC (48)
Immunoglobulin G1-Lambda2, Anti-(Severe Acute Respiratory Syndrome (Human) Coronavirus 2 (Sars-Cov-2) Spike (S) Glycoprotein, Receptor Binding Domain (Rbd)), Homo Sapiens Monoclonal Antibod
Leukemia
Imperial College Healthcare NHS TrustP2CCC (48)
Ogalvibart
Leukemia
Imperial College Healthcare NHS TrustP2CCC (48)
Sonrotoclax
Leukemia
BeiGeneP2CCC (48)
Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1
Leukemia
GeoVax, Inc.P2CCC (48)
Ebnk-001
Leukemia
Essen BiotechP1/2CC (47)
Interleukin-15
Leukemia
Essen BiotechP1/2CC (47)
Pembrolizumab
Leukemia
Essen BiotechP1/2CC (47)
Anti-Cd30-Car-Transduced T Cells
Leukemia
Affiliated Hospital of Nantong UniversityP1/2CC (46)
IM19 CAR-T cells
Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.P1/2CC (46)
Devimistat
Leukemia
Memorial Sloan Kettering Cancer CenterP2CC (44)
Enasidenib
Leukemia
Tian Yi ZhangP1/2CC (44)
Ala-101
Leukemia
Arovella Therapeutics LtdP1CC (43)
Olverembatinib
Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaP1CC (43)
Rimiducid
Leukemia
Bellicum PharmaceuticalsP1/2CC (42)
Acalabrutinib
Leukemia
Inhye AhnP1/2CC (41)
Atrovastain
Leukemia
Assiut UniversityP1/2CC (41)
bt02
Leukemia
Biotroy TherapeuticsP1/2CC (41)
Capivasertib
Leukemia
University of ChicagoP1/2CC (41)
gdx012
Leukemia
TakedaP1/2CC (41)
Max-40279-01
Leukemia
Maxinovel Pty., Ltd.P1/2CC (41)
Mezigdomide
Leukemia
Memorial Sloan Kettering Cancer CenterP1/2CC (41)
Mosunetuzumab
Leukemia
Inhye AhnP1/2CC (41)
MP0533
Leukemia
Molecular Partners AGP1/2CC (41)
Neratinib
Leukemia
Memorial Sloan Kettering Cancer CenterP1/2CC (41)
Roginolisib
Leukemia
Jennifer R. Brown, MD, PhDP1/2CC (41)
Scri-Car22V2
Leukemia
Seattle Children's HospitalP1/2CC (41)
Tagraxofusp
Leukemia
Jacqueline Garcia, MDP1/2CC (41)
Anti-Cd19 Car T-Cells
Leukemia
Affiliated Hospital of Nantong UniversityEarly P1C (39)
JK500 cells
Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaEarly P1C (39)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells
Leukemia
Medical College of WisconsinP1C (37)
bg1805
Leukemia
Guangzhou Bio-gene Technology Co., LtdP1C (37)
bh-30236
Leukemia
BlossomHill TherapeuticsP1C (37)
cd19/cd22-bispecific car-t cells
Leukemia
Seattle Children's HospitalP1C (37)
cd22 car-t
Leukemia
Stanford UniversityP1C (37)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
Leukemia
Fred Hutchinson Cancer CenterP1C (37)
cg009301 for
Leukemia
Cullgen (Shanghai),IncP1C (37)
Showing 51 to 100 of 124 assets
PreviousPage 2 of 3Next